Guangzhou Baiyunshan Pharmaceutical Holdings (SHA:600332) subsidiary Guangzhou Baiyunshan Mingxing Pharmaceutical received supplementary drug approval from China's National Medical Products Administration for its norepinephrine bitartrate injection.
The drug approval covers drug prescription and manufacturing processes, registration, packaging materials, and revision of drug instructions.
The drug is indicated for low blood pressure control.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.